- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Biodesix, Inc.: Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit | 1 | GlobeNewswire (USA) | ||
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| 01.10. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 19.09. | Canaccord senkt Kursziel für Biodesix auf 20 US-Dollar, bestätigt aber Kaufempfehlung | 2 | Investing.com Deutsch | ||
| 19.09. | Biodesix stock price target lowered to $20 by Canaccord, maintains Buy rating | 1 | Investing.com | ||
| 11.09. | Biodesix, Inc.: Biodesix Announces One-for-Twenty Reverse Stock Split | 107 | GlobeNewswire (Europe) | LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) ("Biodesix" or the "Company"), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock... ► Artikel lesen | |
| 11.09. | BIODESIX INC - 8-K, Current Report | 3 | SEC Filings | ||
| 04.09. | Biodesix Stock Surges Over 51% Overnight After Jack Schuler's $1.5M Share Purchase Revealed | 2 | Benzinga.com | ||
| 19.08. | Biodesix, Inc.: Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics | 5 | GlobeNewswire (USA) | ||
| 07.08. | Biodesix GAAP EPS of -$0.08 misses by $0.01, revenue of $20M beats by $1.53M | 2 | Seeking Alpha | ||
| 07.08. | BIODESIX INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.08. | Biodesix, Inc.: Biodesix Announces Second Quarter 2025 Results and Highlights | 168 | GlobeNewswire (Europe) | Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance... ► Artikel lesen | |
| 07.08. | BIODESIX INC - 8-K, Current Report | 2 | SEC Filings | ||
| 24.07. | Biodesix, Inc.: Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025 | 1 | GlobeNewswire (USA) | ||
| 10.06. | Biodesix, Inc.: Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs | 1 | GlobeNewswire (USA) | ||
| 04.06. | Biodesix auf der 45. jährlichen William Blair Growth Stock Konferenz: Fokus auf Lungengesundheit | 3 | Investing.com Deutsch | ||
| 30.05. | BIODESIX INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 22.05. | Biodesix, Inc.: Biodesix Announces New Data on the VeriStrat Test to be Presented at the 2025 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 21.05. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 21.05. | Scotiabank cuts Biodesix stock target to $2, maintains outlook | 3 | Investing.com | ||
| 15.05. | Biodesix, Inc.: Biodesix Announces New Clinical and Economic Data for its Nodify Lung Tests at ISPOR and ATS | 149 | GlobeNewswire (Europe) | LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 13,990 | -0,50 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ARCELLX | 85,21 | +0,95 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| CG ONCOLOGY | 38,000 | -0,24 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| QIAGEN | 40,155 | +0,06 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| GALECTO | 17,990 | 0,00 % | Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble | ||
| ARVINAS | 9,300 | -3,23 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| COGENT BIOSCIENCES | 15,440 | -2,89 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| BIONTECH | 91,00 | +1,34 % | Pfizer prescht nach vorne, BioNTech gerät unter Druck, Eli Lilly feiert eine neue Zulassung und AstraZeneca zieht es nach New York | Wieder einmal überschlagen die Dinge sich in der US-Politik, wobei das Thema Gesundheit eine wichtige Rolle spielt. Reibereien über die staatliche Gesundheitsfürsorge gelten als einer der Hauptgründe... ► Artikel lesen | |
| DISC MEDICINE | 67,89 | -2,01 % | Disc Medicine Inc: Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) | Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30,... ► Artikel lesen | |
| EVOTEC | 6,778 | -1,74 % | Evotec-Aktie: Das sah schon schlechter aus! Jetzt einsteigen? | © Foto: CDC auf UnsplashVom Hamburger Wirkstoffforscher Evotec war in den vergangenen Wochen nur wenig zu hören. Der Aktie hat das nicht geschadet, im Gegenteil.
Evotec: Die Ruhe hat der Aktie nicht... ► Artikel lesen | |
| TOURMALINE BIO | 47,890 | +0,03 % | Novartis Pharma AG: Novartis announces commencement of tender offer to acquire Tourmaline Bio | Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ("Purchaser"), has commenced a tender offer... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 28,420 | 0,00 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
| MAZE THERAPEUTICS | 27,860 | +1,31 % | Maze Therapeutics, Inc.: Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors | SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,225 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 9,280 | 0,00 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen |
BIODESIX INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 7,300 Euro und damit -4,32 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.